United Therapeutics Co. (NASDAQ:UTHR) CEO Sells $851,292.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction on Monday, April 22nd. The stock was sold at an average price of $236.47, for a total value of $851,292.00. Following the sale, the chief executive officer now directly owns 130 shares in the company, valued at $30,741.10. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

United Therapeutics Stock Down 0.4 %

Shares of UTHR opened at $235.95 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.28 and a current ratio of 4.41. United Therapeutics Co. has a 52 week low of $204.44 and a 52 week high of $261.54. The stock has a market capitalization of $11.10 billion, a price-to-earnings ratio of 11.89 and a beta of 0.52. The stock has a fifty day moving average of $233.36 and a 200-day moving average of $228.79.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 EPS for the quarter, beating the consensus estimate of $4.28 by $0.08. The firm had revenue of $614.70 million during the quarter, compared to the consensus estimate of $575.01 million. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The business’s quarterly revenue was up 25.1% on a year-over-year basis. During the same period last year, the company earned $2.67 earnings per share. As a group, sell-side analysts anticipate that United Therapeutics Co. will post 23.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On United Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Rise Advisors LLC acquired a new position in United Therapeutics in the 1st quarter valued at approximately $32,000. GAMMA Investing LLC bought a new position in United Therapeutics during the 4th quarter worth $43,000. C M Bidwell & Associates Ltd. acquired a new position in United Therapeutics during the 3rd quarter worth about $91,000. Ronald Blue Trust Inc. grew its position in shares of United Therapeutics by 155.9% in the 3rd quarter. Ronald Blue Trust Inc. now owns 458 shares of the biotechnology company’s stock valued at $101,000 after buying an additional 279 shares during the last quarter. Finally, Janiczek Wealth Management LLC increased its stake in shares of United Therapeutics by 21.1% in the first quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 84 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on UTHR shares. HC Wainwright reiterated a “buy” rating and set a $300.00 price objective on shares of United Therapeutics in a research note on Thursday, February 22nd. Wedbush reissued an “outperform” rating and issued a $308.00 price objective on shares of United Therapeutics in a research note on Thursday, February 22nd. Wells Fargo & Company upped their target price on United Therapeutics from $309.00 to $325.00 and gave the stock an “overweight” rating in a research note on Thursday, March 7th. SVB Leerink assumed coverage on United Therapeutics in a report on Monday, February 5th. They issued an “outperform” rating and a $330.00 target price on the stock. Finally, StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 11th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $294.25.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.